Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: Effects of the atypical antipsychotic quetiapine

International Journal of Neuropsychopharmacology

Volumn 14, Issue 1, 2011, Pages 43-51

  Leweke, F Markus ^a   Schneider, Miriam ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cannabinoid; puberty; quetiapine.; schizophrenia; social behaviour

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; QUETIAPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EXPOSURE; FEMALE; MALE; MEMORY; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL DISORDER; PUBERTY; RAT; SCHIZOPHRENIA; SOCIAL DISCRIMINATION; SOCIAL INTERACTION; THERAPY EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZOXAZINES; CANNABINOIDS; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; GROOMING; MALE; MEMORY; MORPHOLINES; NAPHTHALENES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SEXUAL MATURATION; SOCIAL BEHAVIOR; TIME FACTORS;

EID: 79952768701     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000842     Document Type: Article

References (37)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press.
2. Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110-117. (Pubitemid 38186851)
3. Caspi A, Moffitt TE, Cannon M, McClay J, et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by functional polymorphism in the catechol-O-methyltransferase gen: longitudinal evidence of a generenvironment interaction. Biological Psychiatry 57, 1117-1127. (Pubitemid 40615773)
4. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15. (Pubitemid 32304342)
5. Ellenbroek BA, Lubbers LJ, Cools AR (1996). Activity of 'seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15, 406-416. (Pubitemid 26342924)
6. Emrich HM, Leweke FM, Schneider U (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology Biochemistry and Behavior 56, 803-807. (Pubitemid 27189767)
7. Everts HGJ, Koolhaas JM (1997). Lateral septal vasopressin in rats: role in social and object recognitioni Brain Research 760, 1-7. (Pubitemid 27304129)
8. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114. (Pubitemid 39486563)
9. Hall W, Degenhardt L (2000). Cannabis use and psychosis: a review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry 34, 26-34. (Pubitemid 34692842)
10. Harvey PD, Patterson TL, Potter LS, Zhong K, et al. (2006). Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine vs. risperidone for social competence, social cognition, and neuropsychological functioning. American Journal of Psychiatry 163, 1918-1925. (Pubitemid 44807783)
11. Jockers-Scherübl MC, Matthies U, Danker-Hopfe H, Lang UE, et al. (2003). Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. Journal of Psychopharmacology 17, 439-445. (Pubitemid 38076340)
12. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, et al. (2006). Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology 26, 453-461. (Pubitemid 44401463)
13. Koethe D, Hoyer C, Leweke FM (2009). The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berlin) 206, 551-561.
14. Konings M, Henquet C, Maharajh HD, Hutchinson G, et al. (2008). Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica 118, 209-213.
15. Leweke FM, Giuffrida A, Wurster U, Emrich HM, et al. (1999a). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669. (Pubitemid 29354290)
16. Leweke FM, Schneider U, Thies M, Munte TF, et al. (1999b). Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142, 230-235. (Pubitemid 29200149)
17. Li M, Davidson P, Budin R, Kapur S, et al. (2004). Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. Schizophrenia Research 70, 69-80. (Pubitemid 38916630)
18. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
19. O'Shea M, Singh ME, McGregor IS, Mallet PE (2004). Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. Journal of Psychopharmacology 18, 502-508. (Pubitemid 39665118)
20. Orsetti M, Canonico PL, Dellarole A, Colella L, et al. (2007). Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 32, 1783-1790. (Pubitemid 47076374)
21. Pellis SM, Field EF, Smith LK, and Pellis VC (1997). Multiple differences in the play fighting of male and female rats. Implications for the causes and functions of play. Neuroscience & Biobehavioral Reviews 21, 105-120. (Pubitemid 27044554)
22. Pellis SM, Pellis VC, Wishaw IQ (1992). The role of the cortex in play fighting by rats: developmental and evolutionary implications. Brain, Behavior and Evolution 39, 270-284.
23. Quinn HR, Matsumoto I, Callaghan PD, Long LE, et al. (2008). Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33, 1113-1126. (Pubitemid 351367534)
24. Robertson BJ, Boon F, Cain DP, Vanderwolf CH (1999). Behavioral effects of anti-muscarinic, anti-serotonergic, and anti-NMDA treatments: hippocampal and neocortical slow wave electrophysiology predict the effects on grooming in the rat. Brain Research 838, 234-240. (Pubitemid 29389842)
25. Schneider M (2008). Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addiction Biology 13, 253-263. (Pubitemid 351692985)
26. Schneider M, Koch M (2002). The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behavioural Pharmacology 13, 29-37. (Pubitemid 34174529)
27. Schneider M, Koch M (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769. (Pubitemid 41070841)
28. Schneider M, Koch M (2005). Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30, 944-957. (Pubitemid 40570910)
29. Schneider M, Koch M (2007). The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. European Neuropsychopharmacology 17, 180-186. (Pubitemid 44779191)
30. Schneider M, Schomig E, Leweke FM (2008). Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addiction Biology 13, 345-357.
31. Skosnik PD, Spatz-Glenn L, Park S (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 48, 83-92. (Pubitemid 32241185)
32. Swartz MS, Perkins DO, Stroup TS, Davis SM, et al. (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 164, 428-436. (Pubitemid 46513156)
33. Tyson PJ, Laws KR, Flowers KA, Tyson A, et al. (2006). Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry and Clinical Neurosciences 60, 473-479. (Pubitemid 44060805)
34. Uchida N, Egashira N, Iwasaki K, Ishibashi A, et al. (2009). Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents. Biological & Pharmaceutical Bulletin 32, 372-375.
35. Vanderschuren LJ, Niesink RJ, Van Ree JM (1997). The neurobiology of social play behavior in rats. Neuroscience & Biobehavioral Reviews 21, 309-326. (Pubitemid 27225153)
36. Veen ND, Selten JP, van der Tweel I, Feller WG, et al. (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry 161, 501-506.
37. Zorilla EP (1997). Multiparous species present problems (and possibilities) to developmentalists. Developmental Psychobiology 30, 141-150.